27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) shot up this week as the FDA announced an accelerated approval of the company’s treatment for Duchenne Muscular Dystrophy, Eteplirsen.
Sarepta’s star continued to shine brightly as the company announced pricing for its drug Monday night.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Traders and investors could have seen this coming as early as the evening of September 13 by following news on the Benzinga Pro platform. Benzinga analysts were first to confirm Twitter reports that a regulator opposed to Sarepta’s treatment had left the agency.
Since that initial report, the company’s share price has more than doubled. It sat at $56.47 at press time, from $25.60 at the time of that initial report.
Benzinga analysts have seen double-digit share price movements off multiple breaking stories in recent weeks, including Weight Watchers International Inc (NYSE: WTW) and Zillow Group Inc (NASDAQ: Z).
Those interested in trying the Benzinga Pro platform can request a free trial here.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.